Results 151 to 160 of about 2,524 (195)
Some of the next articles are maybe not open access.
Nirsevimab and Hospitalization for RSV Bronchiolitis
New England Journal of MedicineRespiratory syncytial virus (RSV) is the leading cause of bronchiolitis, resulting in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody against RSV that has an extended half-life. Its postlicensure real-world effectiveness against RSV-associated bronchiolitis is unclear.We conducted a prospective, multicenter, matched ...
Camille Jung +2 more
exaly +4 more sources
Formulary Drug Reviews: Nirsevimab
Hospital Pharmacy, 2023Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Terri L. Levien, Danial E. Baker
openaire +2 more sources
Nirsevimab for Prevention of RSV Hospitalizations in Infants
New England Journal of MedicineTalkad S Raghuveer +2 more
exaly +4 more sources
Drugs, 2022
Nirsevimab (Beyfortus®), a long-acting intramuscular recombinant neutralising human IgG1ĸ monoclonal antibody to the prefusion conformation of the respiratory syncytial virus (RSV) F protein that has been modified with a triple amino acid substitution in the Fc region to extend the serum half-life, is being jointly developed by AstraZeneca and Sanofi ...
openaire +2 more sources
Nirsevimab (Beyfortus®), a long-acting intramuscular recombinant neutralising human IgG1ĸ monoclonal antibody to the prefusion conformation of the respiratory syncytial virus (RSV) F protein that has been modified with a triple amino acid substitution in the Fc region to extend the serum half-life, is being jointly developed by AstraZeneca and Sanofi ...
openaire +2 more sources
Lancet Regional Health - Europe, TheInternational audienceRespiratory syncytial virus (RSV) is the leading cause of lower-respiratory-tract infection in children. Nirsevimab, a monoclonal antibody against RSV, was implemented in a few countries in September 2023.
Andreas Werner, Corinne Levy, Zein Assad
exaly +2 more sources
Preventive Paediatrics
Respiratory syncytial virus (RSV) is a dominating respiratory infection worldwide. It is responsible for infecting millions of children worldwide each winter through highly contagious droplets and secretions. Over 2.1 million of these children require some form of medical attention during illness.
Ivana Kalanovic Dylag, Andrew Dylag
openaire +1 more source
Respiratory syncytial virus (RSV) is a dominating respiratory infection worldwide. It is responsible for infecting millions of children worldwide each winter through highly contagious droplets and secretions. Over 2.1 million of these children require some form of medical attention during illness.
Ivana Kalanovic Dylag, Andrew Dylag
openaire +1 more source